Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder

References

• Alper, K. R. 2001. Ibogaine: A review. The Alkaloids: Chemistry and Biology 56:1–38.
   PubMedGoogle Scholar
• Alper, K. R., D. Beal, and C. D. Kaplan. 2001. A contemporary history of ibogaine treatment. The Alkaloids: Chemistry and Biology 56:249–81.
   PubMedGoogle Scholar
• Alper, K. R., H. S. Lotsof, and C. D. Kaplan. 2008. The ibogaine medical subculture. Journal of Ethnopharmacology 115:9–24. doi:10.1016/j.jep.2007.08.034.
   PubMed Web of Science ®Google Scholar
• Alper, K. R., M. Stajic, and J. R. Gill. 2012. Fatalities temporally associated with the ingestion of ibogaine. Journal of Forensic Science 57:398–412. doi:10.1111/j.1556-4029.2011.02008.x.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders, text revision (DSM- IV-TR). Washington, DC: American Psychiatric Association.
   Google Scholar
• ATLAS.ti. 2018. ATLAS.ti 8.3.1 for Mac. Berlin: Scientific software development GmbH.
   Google Scholar
• Baumann, M. H., J. Pablo, S. F. Ali, R. B. Rothman, and D. C. Mash. 2001. Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine. The Alkaloids: Chemistry and Biology 56:79–113.
   PubMedGoogle Scholar
• Beal, D., and P. de Rienzo. 1997. Report on the staten island project. The ibogaine story. Brooklyn, New York: Autonomedia.
   Google Scholar
• Beck, A. T., R. A. Steer, and G. K. Brown. 1996. Beck depression inventory-II. San Antonio 78 (2):490–98.
   Google Scholar
• Brown, T. K. 2017. Evidence for the efficacy and transformative power of ibogaine in the treatment of substance dependence. Oakland, California, USA: Psychedelic Science 2017.
   Google Scholar
• Brown, T. K., and K. R. Alper. 2018. Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse 44 (1):24–36. doi:10.1080/00952990.2017.1320802.
   PubMed Web of Science ®Google Scholar
• Camlin, T. J., D. Eulert, A. T. Horvath, S. F. Bucky, J. P. Barsuglia, and M. Polanco. 2018. A phenomenological investigation into the lived experience of ibogaine and its potential to treat opioid use disorders. Journal of Psychedelic Studies 2 (1):1–12. doi:10.1556/2054.2018.004.
   Google Scholar
• Davis, A. K., E. Renn, A. Windham-Herman, M. Polanco, and J. P. Barsuglia. 2018. A mixed-method analysis of persisting effects associated with positive outcomes following ibogaine detoxification”. Journal of Psychoactive Drugs 50 (4):287–97. doi:10.1080/02791072.2018.1487607.
   PubMed Web of Science ®Google Scholar
• Davis, A. K., J. P. Barsuglia, A. Windham-Herman, M. Lynch, and M. Polanco. 2017. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short-and long-term outcomes and current psychological functioning. Journal of Psychedelic Studies 1:65–73. doi:10.1556/2054.01.2017.009.
   PubMedGoogle Scholar
• Dittrich, A., D. Lamparter, and M. Maurer. 2011. 5D-ASC: Questionnaire for the assessment of altered states of consciousness: A short introduction. Zurich, Switzerland: PSIN PLUS Publications.
   Google Scholar
• Frenken, G. 2001. From the roots up: Ibogaine and addict self-help. The Alkaloids: Chemistry and Biology 56:283–92.
   PubMedGoogle Scholar
• Galanter, M., H. Dermatis, S. Post, and C. Sampson. 2013. Spirituality-based recovery from drug addiction in the twelve-step fellowship of narcotics anonymous. Journal of Addiction Medicine 7 (3):189–95. doi:10.1097/ADM.0b013e31828a0265.
   PubMed Web of Science ®Google Scholar
• Glick, S. D., I. M. Maisonneuve, and K. K. Szumlinski. 2000. 18‐Methoxycoronaridine (18‐MC) and ibogaine: Comparison of antiaddictive efficacy, toxicity, and mechanisms of action. Annals of the New York Academy of Sciences 914 (1):369–86. doi:10.1111/j.1749-6632.2000.tb05211.x.
   PubMed Web of Science ®Google Scholar
• Glue, P., H. Winter, K. Garbe, H. Jakobi, A. Lyudin, Z. Lenagh‐Glue, and C. Tak Hung. 2015. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. The Journal of Clinical Pharmacology 55 (6):680–87. doi:10.1002/jcph.471.
   PubMed Web of Science ®Google Scholar
• Goutarel, R., O. Gollnhofer, and R. Sillans. 1993. Pharmacodynamics and therapeutic applications of iboga and ibogaine. Psychedelic Monographs and Essays 6:70–111.
   Google Scholar
• Griffiths, R. R., W. A. Richards, M. W. Johnson, U. D. McCann, and R. Jesse. 2008. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology 22 (6):621–32. doi:10.1177/0269881108094300.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., W. A. Richards, U. McCann, and R. Jesse. 2006. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.”. Psychopharmacology 187 (3):268–83. doi:10.1007/s00213-006-0457-5.
   PubMed Web of Science ®Google Scholar
• Heink, A., S. Katsikas, and T. Lange-Altman. 2017. Examination of the phenomenology of the ibogaine treatment experience: Role of altered states of consciousness and psychedelic experiences. Journal of Psychoactive Drugs 49 (3):201–08. doi:10.1080/02791072.2017.1290855.
   PubMed Web of Science ®Google Scholar
• Hood, R. W., Jr. 1975. The construction and preliminary validation of a measure of reported mystical experience. Journal for the Scientific Study of Religion 14:29–41. doi:10.2307/1384454.
   Web of Science ®Google Scholar
• Kellogg, S. 1993. Identity and recovery. Psychotherapy: Theory, Research, Practice, Training 30 (2):235.
   Web of Science ®Google Scholar
• Lotsof, H. S. 2007. Howard Lotsof (RIP) speaks about ibogain. Accessed October 27, 2018. https://www.youtube.com/watch?v=TezytTw72Bg.
   Google Scholar
• Lotsof, H. S., and N. E. Alexander. 2001. Case studies of ibogaine treatment: Implications for patient management studies. The Alkaloids: Chemistry and Biology 56:293–313.
   PubMedGoogle Scholar
• Mačiulaitis, R., V. Kontrimavičiūtė, F. M. M. Bressolle, and V. Briedis. 2008. Ibogaine, an anti-addictive drug: Pharmacology and time to go further in development. A narrative review. Human & Experimental Toxicology 27 (3):181–94. doi:10.1177/0960327107087802.
   PubMed Web of Science ®Google Scholar
• MacLean, K. A., J. S. Leoutsakos, M. W. Johnson, and R. R. Griffiths. 2012. Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. Journal for the Scientific Study of Religion 51 (4):721–37. doi:10.1111/j.1468-5906.2012.01685.x.
   PubMed Web of Science ®Google Scholar
• MacLean, K. A., M. W. Johnson, and R. R. Griffiths. 2011. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology 25 (11):1453–61. doi:10.1177/0269881111420188.
   PubMed Web of Science ®Google Scholar
• Mash, D. C. 2010. Ibogaine therapy for substance abuse disorders. In: Brizer, D, Castaneda, R., editors. Clinical Addictions Psychiatry. Cambridge University Press. pp. 50–60.
   Google Scholar
• Mash, D. C., C. A. Kovera, B. E. Buck, M. D. Norenberg, P. Shapshak, W. L. Hearn, and J. U. A. N. Sanchez‐Ramos. 1998. Medication development of ibogaine as a pharmacotherapy for drug dependence. Annals of the New York Academy of Sciences 844 (1):274–92. doi:10.1111/j.1749-6632.1998.tb08242.x.
   Web of Science ®Google Scholar
• Mash, D. C., C. A. Kovera, J. Pablo, R. Tyndale, F. R. Ervin, J. D. Kamlet, and W. L. Hearn. 2001. Ibogaine in the treatment of heroin withdrawal. The Alkaloids: Chemistry and Biology 56:155–71.
   PubMedGoogle Scholar
• Mash, D. C., L. Duque, B. Page, and K. Allen-Ferdinand. 2018. Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes. Frontiers in Pharmacology 9:529. doi:10.3389/fphar.2018.00529.
   PubMed Web of Science ®Google Scholar
• McHugh, M. L. 2012. Interrater reliability: The kappa statistic. Biochemia medica: Biochemia medica 22 (3):276–82. doi:10.11613/BM.2012.031.
   PubMed Web of Science ®Google Scholar
• McLellan, A. T., J. Cacciola, D. Carise, and T. H. Coyne. 1999. Addiction severity index–lite (clinical training version). Philadelphia, PA: Treatment Research Institute.
   Google Scholar
• Naranjo, C. 1969. Psycotherapeutic possibilities of new fantasy-enhancing drugs. Clinical Toxicology 2 (2):209–24. doi:10.3109/15563656908990930.
   Web of Science ®Google Scholar
• Naranjo, C. 1974. The healing journey. New York, NY: Ballantine Books.
   Google Scholar
• Nichols, D. E. 2004. Hallucinogens. Pharmacology and Therapeutics 101 (2):131–81. doi:10.1016/j.pharmthera.2003.11.002.
   PubMed Web of Science ®Google Scholar
• Noller, G. E., C. M. Frampton, and B. Yazar-Klosinski. 2018. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse 44 (1):37–46.
   PubMed Web of Science ®Google Scholar
• Onwuegbuzie, A. J., and N. L. Leech. 2007. Validity and qualitative research: An oxymoron? Quality & Quantity 41 (2):233–49. doi:10.1007/s11135-006-9000-3.
   Web of Science ®Google Scholar
• Pahnke, W. N., and W. A. Richards. 1966. Implications of LSD and experimental mysticism. Journal of Religion and Health 5 (3):175–208. doi:10.1007/BF01532646.
   PubMedGoogle Scholar
• Popik, P., R. T. Layer, and P. Skolnick. 1995. 100 years of ibogaine: Neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacological Reviews 47 (2):235–54.
   PubMed Web of Science ®Google Scholar
• Rodger, J. 2018. Understanding the healing potential of ibogaine through a comparative and interpretive phenomenology of the visionary experience. Anthropology of Consciousness 29 (1):77–119. doi:10.1111/anoc.12088.
   Web of Science ®Google Scholar
• Rothen, N., B. Meier, and J. Ward. 2012. Enhanced memory ability: Insights from synaesthesia. Neuroscience & Biobehavioral Reviews 36 (8):1952–63. doi:10.1016/j.neubiorev.2012.05.004.
   PubMed Web of Science ®Google Scholar
• Schenberg, E. E., M. A. de Castro Comis, B. R. Chaves, and D. X. Silveira. 2014. Treating drug dependence with the aid of ibogaine: A retrospective study. Journal of Psychopharmacology 28 (11):993–1000. doi:10.1177/0269881114552713.
   PubMed Web of Science ®Google Scholar
• Schenberg, E. E., M. A. de Castro Comis, J. F. M. Alexandre, B. D. R. Chaves, L. F. Tófoli, and D. X. Da Silveira. 2016. Treating drug dependence with the aid of ibogaine: A qualitative study. Journal of Psychedelic Studies 1 (1):10–19. doi:10.1556/2054.01.2016.002.
   Google Scholar
• Schenberg, E. E., M. A. de Castro Comis, J. F. M. Alexandre, L. F. Tófoli, B. D. Rasmussen Chaves, and D. X. Da Silveira. 2017. A phenomenological analysis of the subjective experience elicited by ibogaine in the context of a drug dependence treatment. Journal of Psychedelic Studies 1 (2):74–83. doi:10.1556/2054.01.2017.007.
   Google Scholar
• Stolaroff, M. J. 2004. The secret chief revealed. Santa Cruz: Multidisciplinary Association for Psychedelic Studies.
   Google Scholar
• Thomas, D. R. 2006. A general inductive approach for analyzing qualitative evaluation data. American Journal of Evaluation 27 (2):237–46. doi:10.1177/1098214005283748.
   Web of Science ®Google Scholar
• Turner, W. J. 1963. Experiences with primary process thinking. Psychiatric Quarterly 37 (3):476–88.
   PubMed Web of Science ®Google Scholar
• Zinberg, N. E. 1984. Drug, set, and setting: The basis for controlled intoxicant use. New Haven, Connecticut: Yale University Press.
   Google Scholar